Drugs Acting on Fetal Growth Abnormalities: A Comprehensive Overview
Description
Fetal growth abnormalities pose a challenge on a significant manner to maternal and child health, influencing well_ being of both mother and baby. Many factors such as environmental, genetic and maternal conditions, can correlate with deviations particularly in fetal growth. Folic acid is a critical B_ vitamin that plays an important role in fetal development particularly in the early stages of pregnancy. Deficiencies of folic acid can result in neural tube defects as well as growth abnormalities. Growth hormone therapy activates skeletal and organ growth particularly regarding the development of fetus. Low_ dose aspirin helps in stopping pre_ eclampsia and fetal growth. Pre eclampsia, a condition manifested by high blood pressure, can result in restricted blood flow to the fetus, influencing it's growth. Corticosteroids namely betamethasone, are used if preterm birth is imminent. These drugs assist in enhancing fetal lung maturation and decrease the risk of respiratory distress syndrome (RDS), frequently associated with preterm births. Antibiotics may be preferred to treat infections, stopping their potential impact on the developing fetus Gestational diabetes plays an important role regarding fetal over growth (macrosimia). An administration of magnesium sulfate is required especially in cases of preterm labor to provide protection to the fetal brain especially from potential damage. It is essentially is seen in Cerebral palsy. Finally it is concluded that drugs play a critical role especially in managing these abnormalities.
Files
Drugs Acting on Fetal Growth Abnormalities -Formatted Paper.pdf
Files
(295.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:18af1316ea999a7ac63b3798eade4980
|
295.0 kB | Preview Download |
Additional details
References
- 1. Romo, A., Carceller, R., & Tobajas, J. (2009). Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatric endocrinology reviews: PER, 6, 332-336.
- 2. Sharma, D., Shastri, S., & Sharma, P. (2016). Intrauterine growth restriction: antenatal and postnatal aspects. Clinical Medicine Insights: Pediatrics, 10, CMPed-S40070.
- 3. Lee, P. A., Chernausek, S. D., Hokken-Koelega, A. C., Czernichow, P., & International SGA Advisory Board. (2003). International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24–October 1, 2001. Pediatrics, 111(6), 1253-1261.
- 4. Faraci, M., Renda, E., Monte, S., Di Prima, F. A., Valenti, O., De Domenico, R., ... & Hyseni, E. (2011). Fetal growth restriction: current perspectives. Journal of prenatal medicine, 5(2), 31.
- 5. Longo, S., Borghesi, A., Tzialla, C., & Stronati, M. (2014). IUGR and infections. Early human development, 90, S42-S44.
- 6. Uzan, J., Carbonnel, M., Piconne, O., Asmar, R., & Ayoubi, J. M. (2011). Pre-eclampsia: pathophysiology, diagnosis, and management. Vascular health and risk management, 467-474.
- 7. Rotshenker-Olshinka, K., Michaeli, J., Srebnik, N., Terlezky, S., Schreiber, L., Farkash, R., & Grisaru Granovsky, S. (2019). Recurrent intrauterine growth restriction: characteristic placental histopathological features and association with prenatal vascular Doppler. Archives of gynecology and obstetrics, 300, 1583-1589.
- 8. Morse, K., Williams, A., & Gardosi, J. (2009). Fetal growth screening by fundal height measurement. Best practice & research Clinical obstetrics & gynaecology, 23(6), 809-818.
- 9. Marsico, C., & Kimberlin, D. W. (2017). Congenital Cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment. Italian journal of pediatrics, 43(1), 1-8.
- 10. Witters, G., Van Robays, J., Willekes, C., Coumans, A., Peeters, H., Gyselaers, W., & Fryns, J. P. (2011). Trisomy 13, 18, 21, Triploidy and Turner syndrome: the 5T's. Look at the hands. Facts, views & vision in ObGyn, 3(1), 15.